Compare Stocks: CTNM, COAG, AGIO, and ZLAB

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$30.02 -8.3%	$34.48	$22.24 ▼ $46.00	$1.79B	0.54	1.14 million shs	2.10 million shs
COAG Hemab Therapeutics	$47.55 +0.2%	$34.43	$23.00 ▼ $52.15	$2.22B	N/A	315,500 shs	447,286 shs
CTNM Contineum Therapeutics	$15.49 -1.7%	$13.64	$5.07 ▼ $16.91	$579.11M	0.7	240,807 shs	449,576 shs
ZLAB Zai Lab	$18.27 +0.3%	$18.60	$15.96 ▼ $39.64	$2.08B	0.76	724,363 shs	353,713 shs

7 Best Space Stocks to Own in 2026

The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	-17.44%	-20.12%	+6.61%	-20.03%
COAG Hemab Therapeutics	0.00%	+0.51%	+53.39%	+39.85%	+4,754,999,900.00%
CTNM Contineum Therapeutics	0.00%	+10.17%	+2.58%	+17.35%	+157.74%
ZLAB Zai Lab	0.00%	-4.94%	-4.45%	-15.18%	-52.63%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$30.02 -8.3%	$34.48	$22.24 ▼ $46.00	$1.79B	0.54	1.14 million shs	2.10 million shs
COAG Hemab Therapeutics	$47.55 +0.2%	$34.43	$23.00 ▼ $52.15	$2.22B	N/A	315,500 shs	447,286 shs
CTNM Contineum Therapeutics	$15.49 -1.7%	$13.64	$5.07 ▼ $16.91	$579.11M	0.7	240,807 shs	449,576 shs
ZLAB Zai Lab	$18.27 +0.3%	$18.60	$15.96 ▼ $39.64	$2.08B	0.76	724,363 shs	353,713 shs

7 Best Space Stocks to Own in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	0.00%	-17.44%	-20.12%	+6.61%	-20.03%
COAG Hemab Therapeutics	0.00%	+0.51%	+53.39%	+39.85%	+4,754,999,900.00%
CTNM Contineum Therapeutics	0.00%	+10.17%	+2.58%	+17.35%	+157.74%
ZLAB Zai Lab	0.00%	-4.94%	-4.45%	-15.18%	-52.63%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.40	Hold	$40.88	36.16% Upside
COAG Hemab Therapeutics	2.83	Moderate Buy	$48.00	0.95% Upside
CTNM Contineum Therapeutics	2.40	Hold	$20.25	30.73% Upside
ZLAB Zai Lab	2.71	Moderate Buy	$40.00	118.94% Upside

Current Analyst Ratings Breakdown

Latest CTNM, COAG, AGIO, and ZLAB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/31/2026	AGIO Agios Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$46.00 ➝ $52.00
7/31/2026	AGIO Agios Pharmaceuticals	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$41.00 ➝ $39.00
7/31/2026	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$22.00 ➝ $23.00
7/30/2026	AGIO Agios Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$52.00 ➝ $55.00
7/29/2026	ZLAB Zai Lab	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/21/2026	AGIO Agios Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$54.00 ➝ $52.00
7/17/2026	CTNM Contineum Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	ZLAB Zai Lab	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/13/2026	COAG Hemab Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$39.00 ➝ $47.00
7/13/2026	COAG Hemab Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$42.00 ➝ $55.00
7/13/2026	COAG Hemab Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $52.00

(Data available from 8/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$54.03M	33.04	N/A	N/A	$20.46 per share	1.47
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	$50M	11.58	N/A	N/A	$6.99 per share	2.22
ZLAB Zai Lab	$453.28M	4.59	N/A	N/A	$6.39 per share	2.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	-$412.78M	-$7.01	N/A	N/A	N/A	-418.24%	-34.40%	-31.90%	N/A
COAG Hemab Therapeutics	N/A	-$23.98	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	-$59.98M	-$1.95	N/A	N/A	N/A	N/A	-24.97%	-23.69%	N/A
ZLAB Zai Lab	-$175.54M	-$1.62	N/A	N/A	N/A	-39.29%	-24.32%	-15.52%	8/6/2026 (Estimated)

Latest CTNM, COAG, AGIO, and ZLAB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	ZLAB Zai Lab	-$0.6794	N/A	N/A	N/A	$103.87 million	N/A
7/30/2026	Q2 2026	AGIO Agios Pharmaceuticals	-$1.65	-$1.69	-$0.04	-$1.69	$26.40 million	$44.75 million
7/30/2026	Q2 2026	CTNM Contineum Therapeutics	-$0.4488	-$0.40	+$0.0488	-$0.40	N/A	N/A
5/21/2026	Q1 2026	COAG Hemab Therapeutics	N/A	-$23.98	N/A	-$23.98	N/A	N/A
5/7/2026	Q1 2026	ZLAB Zai Lab	-$0.5262	-$0.46	+$0.0662	-$0.50	$108.43 million	$99.61 million
5/5/2026	Q1 2026	CTNM Contineum Therapeutics	-$0.55	-$0.39	+$0.16	-$0.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
COAG Hemab Therapeutics	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
ZLAB Zai Lab	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.19	13.59
COAG Hemab Therapeutics	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	38.00	38.00
ZLAB Zai Lab	N/A	2.40	2.19

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
COAG Hemab Therapeutics	N/A
CTNM Contineum Therapeutics	N/A
ZLAB Zai Lab	41.65%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	5.40%
COAG Hemab Therapeutics	N/A
CTNM Contineum Therapeutics	7.90%
ZLAB Zai Lab	4.88%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	59.47 million	56.26 million	Optionable
COAG Hemab Therapeutics	72	46.71 million	N/A	N/A
CTNM Contineum Therapeutics	31	37.39 million	34.43 million	N/A
ZLAB Zai Lab	1,784	113.78 million	108.23 million	Optionable

CTNM, COAG, AGIO, and ZLAB Headlines

Recent News About These Companies

Zai Lab (ZLAB) Expected to Announce Earnings on Thursday

July 30 at 2:56 AM | americanbankingnews.com

Zai Lab (ZLAB) to Post Quarterly Earnings on Thursday

July 30 at 2:55 AM | marketbeat.com

Eupraxia Pharmaceuticals (NASDAQ:EPRX) versus Zai Lab (NASDAQ:ZLAB) Head to Head Survey

July 27, 2026 | americanbankingnews.com

Zai Lab to Announce Second Quarter 2026 Financial Results and Recent Corporate Updates on August 6, 2026

July 22, 2026 | businesswire.com

Zai Lab (NASDAQ:ZLAB) Stock Price Up 7% - Still a Buy?

July 15, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Sees Unusually-High Trading Volume - Should You Buy?

July 13, 2026 | marketbeat.com

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

July 10, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) Upgraded at Zacks Research

July 9, 2026 | marketbeat.com

Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 7,026 Shares

July 2, 2026 | insidertrades.com

Zai Lab Limited (ZLAB) Gains EMA Orphan Drug Designation for DLL3-Targeting Cancer Therapy

June 30, 2026 | finance.yahoo.com

Insider Selling: Zai Lab (NASDAQ:ZLAB) CFO Sells $39,529.44 in Stock

June 30, 2026 | insidertrades.com

Zai Lab (NASDAQ:ZLAB) Director William Lis Sells 7,040 Shares of Stock

June 25, 2026 | insidertrades.com

Zai Lab Receives EMA Orphan Drug Designation for Zocilurtatug Pelitecan (Zoci) in Pulmonary Neuroendocrine Carcinomas

June 16, 2026 | finance.yahoo.com

Pfizer, Zai Lab win China nod for cervical cancer therapy Tivdak

June 9, 2026 | msn.com

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical Cancer

June 8, 2026 | businesswire.com

Zai Lab (ZLAB) Is Down 6.0% After Leadership Shake-Up And 2026 Data Focus Has The Bull Case Changed?

June 6, 2026 | finance.yahoo.com

Zai Lab (ZLAB) Announces Senior Leadership Changes

June 6, 2026 | finance.yahoo.com

5 Stocks That Have the Potential to Rise 1000%

June 5, 2026 | insidermonkey.com

Zai Lab (ZLAB) Q1 2026 Earnings Transcript

June 2, 2026 | fool.com

Zai Lab announces departure of president and COO Josh Smiley

May 22, 2026 | msn.com

Zai Lab announces departure of president and COO Josh Smiley

May 22, 2026 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CTNM, COAG, AGIO, and ZLAB Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$30.02 -2.73 (-8.34%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$29.66 -0.36 (-1.22%)

As of 07/31/2026 07:34 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Hemab Therapeutics NASDAQ:COAG

$47.55 +0.08 (+0.17%)

As of 07/31/2026 04:00 PM Eastern

We are a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience. Our mission is to build the leading coagulation company by discovering, developing, and commercializing innovative therapies for the millions of patients worldwide suffering from serious bleeding and thrombotic diseases. Coagulation disorders encompass a broad and heterogeneous group of conditions, and many patients experience significant life-long disease burden due to either a lack of available prophylactic therapies or limitations associated with existing treatment approaches. Our lead asset, sutacimig (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency. Our second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand Disease. We are also advancing multiple preclinical and discovery-stage assets. We estimate that there are approximately an aggregate of 10,000 patients with Glanzmann thrombasthenia and Factor VII deficiency and an aggregate of 120,000 patients with Von Willebrand Disease in the geographies where we intend to commercialize our assets, including the United States, the European Union, Japan, the Gulf Cooperation Council countries and other select regions. With greater disease burden awareness, potential regulatory approvals of new prophylactic options and expanding global reach of these options, we believe the overall number of addressable patients for our clinical-stage assets, and preclinical and discovery stage programs could be greater than we currently estimate. We aim to establish the industry’s leading coagulation franchise through the execution of our “Hemab 2x3 by 2030” strategic roadmap, which is designed to build a franchise consisting of 2 commercial medicines, 2 new late-stage clinical programs, and 2 new early-stage clinical programs by 2030. We have not yet initiated pivotal trials for any of our product candidates, and due to the novel and unproven nature of our programs, their current stage of development and the lack of approved prophylactic therapies to inform endpoint selection and trial design, we may not be able to achieve our strategic goals on the timeline we expect or at all. Our principal executive offices are located in Cambridge, MA.

Contineum Therapeutics NASDAQ:CTNM

$15.49 -0.26 (-1.65%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$15.46 -0.03 (-0.19%)

As of 07/31/2026 04:43 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Zai Lab NASDAQ:ZLAB

$18.27 +0.06 (+0.33%)

Closing price 07/31/2026 04:00 PM Eastern

Extended Trading

$18.28 +0.02 (+0.08%)

As of 07/31/2026 07:34 PM Eastern

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTNM, COAG, AGIO, and ZLAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTNM, COAG, AGIO, and ZLAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTNM, COAG, AGIO, and ZLAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTNM, COAG, AGIO, and ZLAB Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Hemab Therapeutics NASDAQ:COAG

Contineum Therapeutics NASDAQ:CTNM

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CTNM, COAG, AGIO, and ZLAB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CTNM, COAG, AGIO, and ZLAB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CTNM, COAG, AGIO, and ZLAB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CTNM, COAG, AGIO, and ZLAB Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

Hemab Therapeutics NASDAQ:COAG

Contineum Therapeutics NASDAQ:CTNM

Zai Lab NASDAQ:ZLAB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools